Published Online
on March 27, 2006

A more recent version of this article appeared on May 1, 2006

This Article Full Text (PDF) All Versions of this Article: 47/5/1003    most recent 01.HYP.0000215181.60228.f7v1 Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Sugimoto, K. Articles by Kurtz, T. W. Search for Related Content PubMed PubMed Citation Articles by Sugimoto, K. Articles by Kurtz, T. W. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Related Collections Obesity Animal models of human disease Risk Factors Type 2 diabetes Related Article

Submitted on November 4, 2005
Revised on November 27, 2005

Telmisartan But Not Valsartan Increases Caloric Expenditure and Protects Against Weight Gain and Hepatic Steatosis

Ken Sugimoto; Nathan R. Qi; Ludmila Kazdová; Michal Pravenec; Toshio Ogihara; and Theodore W. Kurtz^*

From the Department of Laboratory Medicine (K.S., N.R.Q., T.W.K.), University of California, San Francisco; Department of Geriatric Medicine (K.S., T.O.), Osaka University Graduate School of Medicine, Osaka, Japan; Institute for Clinical and Experimental Medicine (L.K.), Prague, Czech Republic; Institute of Physiology (M.P.), Czech Academy of Sciences, and the Center for Applied Genomics, Prague, Czech Republic.

^* To whom correspondence should be addressed. E-mail: KurtzT{at}Labmed2.ucsf.edu.

Abstract--The potential effects of angiotensin II receptor blockers (ARBs) on adipose tissue biology and body weight are of considerable interest, because these agents are frequently used to treat hypertension in patients who are prone to visceral obesity, the metabolic syndrome, and diabetes. In rats fed a high-fat, high-carbohydrate diet, we compared the effects of 2 ARBs, telmisartan and valsartan, on body weight, food intake, energy expenditure, fat accumulation, fat cell size, and hepatic triglyceride levels. Telmisartan, but not valsartan, promoted increases in caloric expenditure and protected against dietary-induced weight gain. In the telmisartan-treated rats, absolute food intake, but not food intake adjusted for body weight, was lower than in valsartan-treated rats or controls. Telmisartan reduced the accumulation of visceral fat and decreased adipocyte size to a much greater extent than valsartan and was also associated with a significant reduction in hepatic triglyceride levels. Moreover, telmisartan, but not valsartan, increased the expression of both nuclear-encoded and mitochondrial-encoded genes in skeletal muscle known to play important roles in mitochondrial energy metabolism. Thus, in addition to a class effect of ARBs in modulating adipocyte size, these findings raise the possibility that certain molecules, like telmisartan, may have a particularly strong impact on fat cell volume and fat accumulation, as well as distinctive effects on energy metabolism, that may help protect against dietary-induced visceral obesity and weight gain.

Key words: liver • hypertension, obesity • receptors, angiotensin II

Related Article:

Telmisartan: The ACE of ARBs?

Arya M. Sharma
Hypertension 2006 47: 822-823. [Extract] [Full Text] [PDF]

This article has been cited by other articles:

				X. Rong, Y. Li, K. Ebihara, M. Zhao, W. Aini, T. Kusakabe, M. Hirata, L. Miyamoto, M. Murray, and K. Nakao An Adipose Tissue-Independent Insulin-Sensitizing Action of Telmisartan: a Study in Lipodystrophic Mice J. Pharmacol. Exp. Ther., December 1, 2009; 331(3): 1096 - 1103. [Abstract] [Full Text] [PDF]

				K. Yamamoto, M. Ohishi, C. Ho, T. W. Kurtz, and H. Rakugi Telmisartan-Induced Inhibition of Vascular Cell Proliferation Beyond Angiotensin Receptor Blockade and Peroxisome Proliferator-Activated Receptor-{gamma} Activation Hypertension, December 1, 2009; 54(6): 1353 - 1359. [Abstract] [Full Text] [PDF]

				M. Clemenz, N. Frost, M. Schupp, S. Caron, A. Foryst-Ludwig, C. Bohm, M. Hartge, R. Gust, B. Staels, T. Unger, et al. Liver-Specific Peroxisome Proliferator-Activated Receptor {alpha} Target Gene Regulation by the Angiotensin Type 1 Receptor Blocker Telmisartan Diabetes, May 1, 2008; 57(5): 1405 - 1413. [Abstract] [Full Text] [PDF]

				D. Walcher, K. Hess, P. Heinz, K. Petscher, D. Vasic, U. Kintscher, M. Clemenz, M. Hartge, K. Raps, V. Hombach, et al. Telmisartan Inhibits CD4-Positive Lymphocyte Migration Independent of the Angiotensin Type 1 Receptor via Peroxisome Proliferator-Activated Receptor-{gamma} Hypertension, February 1, 2008; 51(2): 259 - 266. [Abstract] [Full Text] [PDF]

				N. Basso, R. Cini, A. Pietrelli, L. Ferder, N. A. Terragno, and F. Inserra Protective effect of long-term angiotensin II inhibition Am J Physiol Heart Circ Physiol, September 1, 2007; 293(3): H1351 - H1358. [Abstract] [Full Text] [PDF]

				A. Zanchi, A. G. Dulloo, C. Perregaux, J.-P. Montani, and M. Burnier Telmisartan prevents the glitazone-induced weight gain without interfering with its insulin-sensitizing properties Am J Physiol Endocrinol Metab, July 1, 2007; 293(1): E91 - E95. [Abstract] [Full Text] [PDF]

				M. Pravenec and T. W. Kurtz Molecular Genetics of Experimental Hypertension and the Metabolic Syndrome: From Gene Pathways to New Therapies Hypertension, May 1, 2007; 49(5): 941 - 952. [Abstract] [Full Text] [PDF]

				A. Remuzzi and G. Remuzzi Review: Potential protective effects of telmisartan on renal function deterioration Journal of Renin-Angiotensin-Aldosterone System, December 1, 2006; 7(4): 185 - 191. [Abstract] [PDF]

				A. M. Sharma Telmisartan: The ACE of ARBs? Hypertension, May 1, 2006; 47(5): 822 - 823. [Full Text] [PDF]